Oncolytics Biotech Inc (ONC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
82
About the Report
About the Report
Summary
Oncolytics Biotech Inc (Oncolytics) is a development stage biopharmaceutical company which focuses on the discovery and development of oncolytic viruses for the treatment of cancer. The company's lead product, Reolysin, a formulation of the human reovirus, is indicated for the treatment of lung, ovarian, colorectal, pancreatic, prostate, breast, head and neck cancers. Reolysin is also undergoing various other clinical trials to determine its use in other types of cancer, such as for squamous cell carcinoma, metastatic colorectal cancer, metastatic melanoma trial, and non-small cell lung cancer. The company and its partners conduct clinical trials across Canada and the US. Oncolytics is headquartered in Calgary, Alberta, Canada.
Oncolytics Biotech Inc (ONC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Oncolytics Biotech Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Oncolytics Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 11
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deal Details 13
Private Equity 13
Oncolytics Biotech to Raise up to USD26 Million in Private Placement of Shares 13
Partnerships 14
Oncolytics Biotech Enters into Agreement with SOLTI 14
Oncolytics Biotech Enters into Research Partnership with Keck School of Medicine of University of Southern California 15
Licensing Agreements 16
Oncolytics Biotech Enters into Licensing Agreement with Adlai Nortye Biopharma 16
Equity Offering 17
Oncolytics Biotech Raises USD8.9 Million in Public Offering of Share 17
Oncolytics Biotech Raises USD8.5 Million in Public Offering of Units 18
Oncolytics Biotech to Raise USD20 Million in Public Offering of Common Stock 19
Oncolytics Biotech Completes First Tranche Of Private Placement Of Shares For USD 1 Million 20
Oncolytics Biotech Completes Public Offering Of Common Stock For USD 32 Million 21
Oncolytics Biotech Completes Private Placement Of Shares For USD 21 Million 22
Oncolytics Biotech Inc-Key Competitors 24
Oncolytics Biotech Inc-Key Employees 25
Oncolytics Biotech Inc-Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Strategy And Business Planning 27
Jun 27, 2017: Oncolytics Biotech Opens U.S. Based Office in San Diego 27
Financial Announcements 28
Aug 03, 2018: Oncolytics Biotech reports 2018 second quarter results 28
May 11, 2018: Oncolytics Biotech Reports 2018 First Quarter Results 29
Mar 09, 2018: Oncolytics Biotech Announces 2017 Year End Results 30
Nov 08, 2017: Oncolytics Biotech Announces 2017 Third Quarter Results 32
Aug 03, 2017: Oncolytics Biotech Announces 2017 Second Quarter Results 33
May 05, 2017: Oncolytics Biotech Announces 2017 First Quarter Results 34
Mar 10, 2017: Oncolytics Biotech Announces 2016 Year-End Results 35
Corporate Communications 36
Jun 01, 2018: Oncolytics Biotech Announces Listing on Nasdaq Capital Market 36
May 29, 2018: Oncolytics Biotech Announces New OTCQX Ticker Symbol 37
Apr 17, 2018: Oncolytics Biotech Announces Resignation Of Andres Gutierrez As Chief Medical Officer 38
Jun 29, 2017: Oncolytics Biotech Appoints Andrew de Guttadauro, President of Oncolytics Biotech 39
Jan 19, 2017: Oncolytics Biotech Appoints Dr. Matt Coffey to the Role of President and CEO 40
Product News 41
12/27/2017: Oncolytics Biotech Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas 41
11/30/2017: Oncolytics Biotech Establishes Scientific Advisory Board Focused on REOLYSIN Registration Study in Metastatic Breast Cancer 42
11/02/2017: Oncolytics Biotech Appoints Deborah Brown to Board of Directors 43
10/02/2018: Oncolytics Biotech announces a publication demonstrating that intravenously delivered oncolytic viruses effectively target tumors even in the presence of neutralizing antibodies 44
09/19/2018: Oncolytics Biotech provides corporate and clinical update 45
09/19/2017: Oncolytics Biotech to Present at the Phacilitate Immuno-Oncology Frontiers Conference 46
09/17/2018: Oncolytics Biotech announces investigator sponsored multiple myeloma study combining REOLYSIN and Nivolumab (Opdivo) with standard of care 47
06/04/2018: Oncolytics Biotech Announces Poster Presentation Demonstrating the Ability of REOLYSIN to Promote and Predict Response to Checkpoint Inhibitors at ASCO 2018 Annual Meeting 48
05/23/2017: Oncolytics Biotech Announces Participation in World Immunotherapy Congress USA 2017 49
05/16/2018: Oncolytics Biotech Announces Publication of REOLYSIN Abstract for the ASCO 2018 Annual Meeting 50
04/18/2018: Oncolytics Biotech Demonstrates Positive Data in Two Posters at AACR Annual Meeting 2018 51
04/10/2018: Oncolytics Biotech Presents Positive REOLYSIN Data in Combination with Keytruda and anti-CD73 at International Oncolytic Virus Conference 2018 52
04/04/2018: Oncolytics Biotech to Present at the MicroCap Conference 53
03/20/2018: Oncolytics Biotech Scientist Selected to Participate in the Society of Immunotherapy of Cancers METIOR Incubator Program 54
03/14/2018: Oncolytics Biotech Announces Publication of REOLYSIN Abstract for the AACR 2018 Annual Meeting 55
02/27/2018: Oncolytics Biotech to Present REOLYSIN at the 2018 Precision: Breast Cancer World R&D Summit 56
01/16/2018: Oncolytics Biotech Announces Abstract for Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas 57
Product Approvals 58
Dec 05, 2017: Oncolytics Biotech Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN in Metastatic Breast Cancer 58
May 08, 2017: Oncolytics Biotech Announces FDA Fast Track Designation for REOLYSIN in Metastatic Breast Cancer 59
Clinical Trials 60
Oct 11, 2018: Oncolytics Biotech announces publication of positive clinical results for Pelareorep in abstract for ESMO 2018 Congress 60
May 17, 2018: Oncolytics Biotech Announces Collaboration with Merck and Northwestern University Combining Keytruda and REOLYSIN in a Phase 2 Second Line Pancreatic Cancer Study 61
May 10, 2018: Oncolytics Biotech Receives Special Protocol Assessment Agreement from FDA for Phase 3 Clinical Trial of Pelareorep In Metastatic Breast Cancer 62
Feb 01, 2018: Oncolytics Biotech to Host Conference Call Outlining the Treatment Paradigm of Metastatic Breast Cancer Subtypes and Provide Topline Information on its Phase 3 Registration Study with REOLYSIN 63
Jan 19, 2018: Oncolytics Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas 64
Dec 04, 2017: Oncolytics Biotech to Present at the Oncolytic Virotherapy Summit 65
Oct 11, 2017: Oncolytics Biotech to Present at the 2017 BIO Investor Forum 66
Sep 18, 2017: Oncolytics Biotech Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN in Metastatic Breast Cancer 67
Sep 14, 2017: Oncolytics Biotech Announces First Patient Treated in MUK eleven Study 68
Sep 11, 2017: Oncolytics Biotech Announces the Presentation of REOLYSIN Clinical Data at ESMO 2017 Congress 69
Jul 26, 2017: Oncolytics Biotech to Present REOLYSIN Safety Data in Combination with Chemotherapy at ESMO 2017 Congress 70
May 17, 2017: Oncolytics Biotech Announces ASCO Abstracts and Preliminary Data for Studies in Pancreatic and Prostate Cancers 71
Apr 27, 2017: Oncolytics Biotech Announces Details of 2017 Annual Meeting of Shareholders 72
Apr 12, 2017: Oncolytics Biotech Announces Registration Pathway and Clinical Development Plan 73
Apr 05, 2017: Oncolytics Biotech's REOLYSIN More than Doubles Overall Survival in Patients with Mutated p53 Metastatic Breast Cancer 75
Mar 31, 2017: Oncolytics Biotech REOLYSIN Provides Statistically Significant Improvement in Overall Survival in Canadian Cancer Trials Group Sponsored Randomized Phase 2 Study in Metastatic Breast Cancer 76
Mar 16, 2017: Myeloma UK launches world-first novel immunotherapy trial 77
Mar 02, 2017: Oncolytics Biotech Announces Canadian Cancer Trials Group to Present Final Randomized Data from Phase 2 Metastatic Breast Cancer Study at AACR 2017 Annual Meeting 78
Other Significant Developments 79
Sep 13, 2018: Viruses show new promise in treating cancer 79
Mar 08, 2018: Oncolytics Biotech Chief Medical Officer to Facilitate Roundtable Discussion at the US Immuno-Oncology Strategy Meeting 81
Appendix 82
Methodology 82
About GlobalData 82
Contact Us 82
Disclaimer 82
List of Figure
List of Figures
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Oncolytics Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 11
List of Table
List of Tables
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Oncolytics Biotech Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Oncolytics Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 11
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Oncolytics Biotech to Raise up to USD26 Million in Private Placement of Shares 13
Oncolytics Biotech Enters into Agreement with SOLTI 14
Oncolytics Biotech Enters into Research Partnership with Keck School of Medicine of University of Southern California 15
Oncolytics Biotech Enters into Licensing Agreement with Adlai Nortye Biopharma 16
Oncolytics Biotech Raises USD8.9 Million in Public Offering of Share 17
Oncolytics Biotech Raises USD8.5 Million in Public Offering of Units 18
Oncolytics Biotech to Raise USD20 Million in Public Offering of Common Stock 19
Oncolytics Biotech Completes First Tranche Of Private Placement Of Shares For USD 1 Million 20
Oncolytics Biotech Completes Public Offering Of Common Stock For USD 32 Million 21
Oncolytics Biotech Completes Private Placement Of Shares For USD 21 Million 22
Oncolytics Biotech Inc, Key Competitors 24
Oncolytics Biotech Inc, Key Employees 25
Oncolytics Biotech Inc, Other Locations 26
Oncolytics Biotech Inc, Subsidiaries 26
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.